Business
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
Preclinical Data Demonstrate EDP-235’s Superior Target Tissue Distribution and Cell Penetration Compared to Other Protease Inhibitors New Preclinical
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nPreclinical Data Demonstrate EDP-235’s Superior Target Tissue Distribution and Cell Penetration Compared to Other Protease Inhibitors\n\n\n\nNew Preclinical Pharmacokinetic Data Highlight EDP-323’s Strong Bioavailability and Favorable Tissue Targeting\n\n\n\n WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced the company will present two posters supporting the continued clinical development of EDP-235, its 3CL protease inhibitor in development as an oral, once-daily treatment for SARS-CoV-2 infection, and EDP-323, its L-protein inhibitor in development as an oral, once-daily treatment for respiratory syncytial virus (RSV), at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18, 2023 both virtually and at the Bella Center Copenhagen in Copenhagen, Denmark.\n\n\nPreclinical data presented demonstrate EDP-235’s preferential target tissue distribution and cell penetration, enabling EDP-235 to reach potential sites of persistent viral replication, which may impact progression of long COVID-19. EDP-235 is currently being evaluated in SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 study of non-hospitalized, symptomatic adults with mild or moderate COVID-19. Enanta continues to expect topline data from the study in May 2023. Additionally, preclinical data presented showcase EDP-323’s favorable preclinical pharmacokinetic (PK) properties, excellent bioavailability with low plasma clearance, and favorable target tissue distribution, supporting a once-daily oral dosing regimen for RSV. EDP-323 is currently being evaluated in a Phase 1 double-blind, placebo-controlled, first-in-human study with a topline data readout planned for the second quarter of 2023.\n\n\n“We are pleased to present these data which highlight the strong and differentiated preclinical profiles of EDP-235 and EDP-323,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “Both our EDP-235 and EDP-323 programs are advancing through clinical development, and we look forward to presenting our Phase 2 SPRINT trial for EDP-235 and Phase 1 study for EDP-323 this quarter. Our robust pipeline and important upcoming milesto...